Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

394 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study.
Buron MD, Chalmer TA, Sellebjerg F, Barzinji I, Danny B, Christensen JR, Christensen MK, Hansen V, Illes Z, Jensen HB, Kant M, Papp V, Petersen T, Prakash S, Rasmussen PV, Schäfer J, Theódórsdóttir Á, Weglewski A, Sorensen PS, Magyari M. Buron MD, et al. Among authors: sorensen ps. Neurology. 2020 Aug 25;95(8):e1041-e1051. doi: 10.1212/WNL.0000000000010135. Epub 2020 Jul 7. Neurology. 2020. PMID: 32636328
Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis.
Sorensen PS, Ross C, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K, Kristensen O, Petersen T, Rasmussen S, Ravnborg M, Stenager E, Koch-Henriksen N; Danish Multiple Sclerosis Study Group. Sorensen PS, et al. Lancet. 2003 Oct 11;362(9391):1184-91. doi: 10.1016/S0140-6736(03)14541-2. Lancet. 2003. PMID: 14568740 Clinical Trial.
Antibodies to IFN-beta: the Danish National IFN-beta Project.
Sorensen PS, Ross C, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K, Kristensen O, Petersen T, Rasmussen S, Ravnborg M, Stenager E, Koch-Henriksen N; Danish Multiple Sclerosis Study Group; Danish Interferon-beta Project. Sorensen PS, et al. Neurology. 2003 Nov 11;61(9 Suppl 5):S27-8. doi: 10.1212/01.wnl.0000092362.44313.b6. Neurology. 2003. PMID: 14610108 Clinical Trial. No abstract available.
Multiple sclerosis: pathophysiology revisited.
Sorensen PS. Sorensen PS. Lancet Neurol. 2005 Jan;4(1):9-10. doi: 10.1016/S1474-4422(04)00948-2. Lancet Neurol. 2005. PMID: 15620850 Review. No abstract available.
Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.
Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, Achiti I, Confavreux C, Coustans M, le Page E, Edan G, McDonnell GV, Hawkins S, Trojano M, Liguori M, Cocco E, Marrosu MG, Tesser F, Leone MA, Weber A, Zipp F, Miterski B, Epplen JT, Oturai A, Sørensen PS, Celius EG, Lara NT, Montalban X, Villoslada P, Silva AM, Marta M, Leite I, Dubois B, Rubio J, Butzkueven H, Kilpatrick T, Mycko MP, Selmaj KW, Rio ME, Sá M, Salemi G, Savettieri G, Hillert J, Compston DA. Roxburgh RH, et al. Among authors: sorensen ps. Neurology. 2005 Apr 12;64(7):1144-51. doi: 10.1212/01.WNL.0000156155.19270.F8. Neurology. 2005. PMID: 15824338
394 results